Lastly, it should be noted that treatment innovations (e.g. newer GLP1 receptor agonists such as semaglutide or tirzepatide for type 2 diabetes) may affect a model’s predictive power over time. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.